Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series

Cancer Treatment Communications

Volumn 7, Issue , 2016, Pages 43-46

  Keith, Kevin C ^a   Lee, Yueh ^b,c   Ewend, Matthew G ^b,c   Zagar, Timothy M ^b,c   Anders, Carey K ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adotrastuzumab; Brain metastasis; Breast cancer; Emtansine; Kadcyla; T DM1

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB EMTANSINE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; ANAPHYLAXIS; APPETITE DISORDER; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SENTINEL LYMPH NODE BIOPSY; SINGLE DRUG DOSE; STEREOTACTIC RADIOSURGERY; UPPER ABDOMINAL PAIN; VOMITING; WHOLE BODY RADIATION;

EID: 84962715605     PISSN: 22130896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrc.2016.03.005     Document Type: Article

References (14)

1. Puhalla S., et al. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol. 2015, 17(5):639-651.
2. Bendell J.C., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97(12):2972-2977.
3. Ewend M.G., et al. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J. Natl. Compr. Cancer Netw. 2008, 6(5):505-513. quiz 514.
4. Swain S.M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015, 372(8):724-734.
5. Verma S. Advances in treating HER2-positive breast cancer: an interview with Sunil Verma. BMC Med. 2014, 12:129.
6. Olson E.M., et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 2013, 22(4):525-531.
7. Vaz-Luis I., et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012, 14(5):R129.
8. Bachelot T., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013, 14(1):64-71.
9. Lockman P.R., et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 2010, 16(23):5664-5678.
10. Ningaraj N.S., et al. Targeted brain tumor treatment-current perspectives. Drug Target Insights 2007, 2:197-207.
11. Askoxylakis V., et al. Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment. J. Natl. Cancer Inst. 2016, 108:2.
12. Krop I.E., et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann. Oncol. 2015, 26(1):113-119.
13. Kalsi R., et al. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin. Breast Cancer 2015, 15(2):e163-e166.
14. Bartsch R., et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin. Exp. Metastasis 2015, 32(7):729-737.